A second study presented at the meeting retrospectively analyzed patient outcomes associated with intravenous self-administration of C1 Esterase Inhibitor (C1-INH), a method that enables patients to treat themselves earlier, at home. The study, conducted over a period of more than 18 months, enrolled a total of 13 HAE patients who were shown how to self-administer. The study found that self-administration of intravenous C1-INH concentrate can be a good option for patients with HAE. Adverse events were rare in the study, and no complications related to home administration were reported.
"Given the importance of timely treatment, the idea of home-based therapy for HAE attacks has gained support in recent years," said Ralph Shapiro, M.D., of the Midwest Immunology Clinic in Plymouth, Minnesota, and the study's lead investigator. "Our findings suggest that self-administration of Berinert can provide patients with a new confidence in managing their HAE symptoms."Berinert is approved for on-demand treatment of acute abdominal, facial or laryngeal attacks of HAE in adults and adolescents, and is also approved for patient self-administration after proper training by a healthcare professional. Dr. Craig was an investigator for both the I.M.P.A.C.T. 1 and I.M.P.A.C.T. 2 studies which were funded by CSL Behring. Dr. Shapiro received an unrestricted grant from CSL Behring for his work analyzing patient outcomes associated with self-administration of Berinert.
About HAEHAE is a rare genetic disorder caused by a deficiency of C1-INH and inherited in an autosomal dominant manner. Symptoms of HAE include episodes of edema, or swelling, in various locations, including the face, abdomen and larynx. Patients who have abdominal attacks of HAE ca
|SOURCE CSL Behring|
Copyright©2010 PR Newswire.
All rights reserved